A nurse is reviewing the medical record of a client diagnosed with depression and notes that the client has been prescribed bupropion (Wellbutrin). The client asks, "What kind of medication is this anyway?" The nurse would inform the client this agent is a:

Choice A reason: Bupropion is an atypical antidepressant, inhibiting dopamine and norepinephrine reuptake, enhancing prefrontal cortex and reward system activity. Unlike SSRIs or MAOIs, it minimally affects serotonin, targeting catecholamines to improve mood and energy, aligning with its unique mechanism in treating depression. Choice B reason: Tricyclic antidepressants block serotonin and norepinephrine reuptake and have anticholinergic effects, unlike bupropion, which targets dopamine and norepinephrine without significant anticholinergic activity. This distinct pharmacological profile excludes bupropion from the tricyclic class, making this choice incorrect. Choice C reason: Selective serotonin reuptake inhibitors like fluoxetine target serotonin exclusively, increasing 5-HT levels. Bupropion primarily inhibits dopamine and norepinephrine reuptake, with minimal serotonin effects, making it an atypical antidepressant, not an SSRI, due to its distinct neurochemical action. Choice D reason: Monoamine oxidase inhibitors like phenelzine prevent monoamine breakdown, increasing serotonin, dopamine, and norepinephrine. Bupropion’s selective reuptake inhibition of dopamine and norepinephrine, without MAO inhibition, distinguishes it as an atypical antidepressant, not an MAOI, due to its specific mechanism.